NCT00494299View on ClinicalTrials.gov

Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

PHASE3CompletedINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

November 30, 2010

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib

DRUG

Placebo

Placebo: matching placebo

Trial Locations (75)

135710

Seoul

460-0001

Nagoya

260-8677

Chiba

277-8577

Kashiwa

791-0280

Matsuyama

791-0295

Tōon

918-8503

Fukui-shi

814-0180

Fukuoka

820-8505

Iizuka

802-8533

Kitakyushu

807-8555

Kitakyushu

830-0011

Kurume

500-8513

Gifu

372-0817

Isesaki

371-8511

Maebashi

730-8619

Hiroshima

734-8530

Hiroshima

734-8551

Hiroshima

737-0193

Kure

003-0804

Sapporo

060-0033

Sapporo

673-8558

Akashi

650-0017

Kobe

309-1793

Kasama

920-8641

Kanazawa

890-0061

Kagoshima

890-8520

Kagoshima

892-8512

Kagoshima

259-1193

Isehara

228-8520

Sagamihara

232-0024

Yokohama

245-8575

Yokohama

860-0008

Kumamoto

860-8556

Kumamoto

861-4193

Kumamoto

606-8507

Kyoto

980-8574

Sendai

983-8520

Sendai

880-0003

Miyazaki

390-8621

Matsumoto

856-8562

Ōmura

700-8511

Okayama

586-8521

Kawachi-Nagano

570-8507

Moriguchi

530-8480

Osaka

534-0021

Osaka

537-8511

Osaka

540-0006

Osaka

543-8555

Osaka

545-8586

Osaka

558-8558

Osaka

589-8511

Sayama

565-0871

Suita

410-2295

Izunokuni

411-8777

Sunto

329-0498

Shimotsuke

104-0045

Chuo-ku

173-8610

Itabashi-ku

152-8902

Meguro-ku

105-8470

Minato-ku

180-8610

Musashino

177-8521

Nerima-ku

160-0023

Shinjuku-ku

683-8504

Yonago

930-8550

Toyama

990-9585

Yamagata

750-0061

Shimonoseki

755-8505

Ube

409-3898

Chūō

152-703

Seoul

700-721

Daegu

405-760

Incheon

110-744

Seoul

138-736

Seoul

Unknown

Seoul

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00494299 - Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE) | Biotech Hunter | Biotech Hunter